Pfizer R&D: If you can’t do it, buy it

Categories: Prescription Drugs

It looks like Pfizer is finally putting some much-needed money into research and development. Pfizer’s not investing internally, of course; it’s just buying another biotech firm in an attempt fill its dwindling pipelines.

This time it’s the privately held BioRexis Pharmaceutical Corporation. According to the Pharma Gazette:

Not disclosing the financial terms of agreement, Pfizer, Inc. is going to acquire BioRexis. Expected to close during the first or second quarter of this year, the acquisition agreement will enable Pfizer an access to BioRexis’ early stage diabetes pipeline and proprietary protein engineering technologies.

For more information, check out the press release.

About Cary Byrd

eDrugSearch founder, Cary Byrd, has been called an “e-health innovator” by MarketIntellNow, interviewed by top pharmaceutical industry journalists, invited to Matthew Holt’s Health 2.0 Conference and a Consumer Report's health summit, and highlighted on numerous health blogs.

eDrugSearch.com - Search. Compare. Save.

Leave a Reply

Join Our Free Newsletter

Please enter email id

Get a weekly dose of money-saving tips on your medications, drug side effects alerts, drug interaction warnings, free prescription coupons, late-breaking safety information and much, much more!

Share via
Copy link